Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » FDA Adds New Safety Warning for Fluoroquinolones

    FDA Adds New Safety Warning for Fluoroquinolones

    Serious complications include delirium, hypoglycemia

    October 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    FDA adds boxed warning on codeine after surgery

    FDA requires adding nerve damage warning to fluoroquinolone labels

    Safety Warning Issued for Fluoroquinolone Antibiotics

    Related Products

    FDA adds boxed warning on codeine after surgery | Single Article

    ED Accreditation Update: New Sentinel Event Alert gives warning: IT implementation has inherent safety risks | Single Article

    FDA issues warning for nonoxynol-9 products | Single Article

    Adding another in a series of label warnings for fluoroquinolones, the FDA is emphasizing that the antibiotics pose too high a risk of patient harm to be used for relatively minor infections.

    These include acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infections, the FDA stated.1

    Fluoroquinolones should be used in such cases only if the patient has no other treatment option, the agency explained.

    The FDA emphasized the risks of mental health effects and serious blood sugar disturbances related to the antibiotics in a July 10, 2018, warning, which applies to both oral and injectable formulations.

    “The new class-wide labeling changes will require that the mental health side effects be listed separately from other central nervous system side effects and be consistent across the labeling of the fluoroquinolone class,” the FDA stated.

    “The mental health side effects to be included in the labeling across all the fluoroquinolones are disturbances in attention, disorientation, agitation, nervousness, memory impairment, and delirium.”

    Additionally, the recent FDA review reported cases where patients on fluoroquinolones experienced hypoglycemia.

    “As a result, the Blood Glucose Disturbances subsection of the labeling for all systemic fluoroquinolones will now be required to explicitly reflect the potential risk of coma with hypoglycemia,” the FDA stated.

    This latest action follows the FDA’s 2016 enhanced warnings about the link between fluoroquinolone use and damage to tendons, muscles, and joints.

    This risk was underscored by a recent CDC guest blog written by Rachel Brummert, BS, MS, president of Patient Safety Impact. Brummert suffered multiple tendon ruptures after being on fluoroquinolones.

    “In addition, I suffer from central and autonomic nervous system damage. This damage is permanent,” she wrote.2

    She also attributed fluoroquinolone use to memory loss, chronic pain, and low blood pressure.

    “I never knew that an antibiotic, which I thought was supposed to help me feel better, could cause an otherwise healthy person like myself to become disabled at 36 years old,” Brummert notes.

    The FDA said that appropriate fluoroquinolone use is still a mainstay treatment for patients.

    Part of the problem is that the antibiotics are being prescribed when they are indicated for first-line therapy and even in cases where treatment is not needed at all.

    According to the FDA,1 currently approved fluoroquinolones include levofloxacin, ciprofloxacin, ciprofloxacin extended-release tablets, moxifloxacin, ofloxacin, gemifloxacin, and delafloxacin.

    REFERENCES

    1. FDA. FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions. July 10, 2018: https://bit.ly/2CpQxyz.
    2. Brummert, R. Prescribed Incorrectly, Lifesaving Antibiotics Can Be Dangerous, Carry Real Risks. Aug. 17, 2018. CDC Safe Healthcare Blog: https://bit.ly/2L5W6kM.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Hospital Infection Control & Prevention

    View PDF
    Hospital Infection Control & Prevention (Vol. 45, No. 10) - October 2018
    October 1, 2018

    Table Of Contents

    Outcasts: HAIs Stigmatize Discharged Patients

    Staffing Woes: IP-Hospital Beds Ratio Outdated

    SHEA: Avoid Routine Testing for C. diff in the NICU

    ‘Why the Foley?’ Initiative Grabs Attention, Prevents CAUTIs

    Joint Commission Revises IC Devices Standard

    FDA Adds New Safety Warning for Fluoroquinolones

    CDC: New Flu Vaccine Ready After Harsh 2017-2018 Season

    EMTs Treating Opioid Patients Succumb to Illness

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Peer Reviewer Patrick Joseph, MD, reports that he is a consultant for Genomic Health Reference Laboratory, Siemens Clinical Laboratory, and CareDx Clinical Laboratory. Senior Writer Gary Evans, Editor Jesse Saffron, Editor Jill Drachenberg, Nurse Planner Patti Grant, RN, BSN, MS, CIC, and Editorial Group Manager Terrey L. Hatcher report no consultant, stockholder, speaker’s bureau, research, or other financial relationships with companies having ties to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2020 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing